Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
Sponsor: Spectrum Pharmaceuticals, Inc
This PHASE1 trial investigates ALL, Childhood and Lymphoblastic Leukemia, Acute and is currently completed. Spectrum Pharmaceuticals, Inc leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
Status: Unknown → Completed
-
Sep 2025 — Nov 2025 [monthly]
Unknown PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
▶ Show 9 earlier versions
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Mar 2019 — May 2020 [monthly]
Recruiting PHASE1
-
Aug 2018 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Spectrum Pharmaceuticals, Inc
- Therapeutic Advances in Childhood Leukemia Consortium
For direct contact, visit the study record on ClinicalTrials.gov .